News
TOVX
0.1400
-2.85%
-0.0041
Weekly Report: what happened at TOVX last week (1109-1113)?
Weekly Report · 1d ago
Theriva Biologics, Inc. Reports Third Quarter 2026 Results and SYN-004 Asset Sale
NASDAQ · 4d ago
Theriva Biologics, Inc. Q3 Loss Drops
NASDAQ · 4d ago
Theriva Biologics GAAP EPS of -$0.03
Seeking Alpha · 4d ago
*Theriva Biologics 3Q Loss/Shr 3c >TOVX
Dow Jones · 4d ago
*Theriva Biologics 3Q Rev $0.00 >TOVX
Dow Jones · 4d ago
Theriva Biologics Q3 EPS $(0.03) Up From $(0.45) YoY
Benzinga · 4d ago
Press Release: Theriva(TM) Biologics Reports -2-
Dow Jones · 4d ago
Press Release: Theriva(TM) Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results
Dow Jones · 4d ago
Weekly Report: what happened at TOVX last week (1102-1106)?
Weekly Report · 11/09 09:47
Theriva Biologics Sells Enzyme Portfolio; Shifts Focus To VCN-01; Stock Up
NASDAQ · 11/03 05:24
Theriva Biologics Completes Sale of SYN-004 and Related Assets
TipRanks · 11/02 21:42
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 11/02 21:05
Theriva Biologics Consensus Price Target Raised 60% to $4.08
NASDAQ · 11/02 13:03
Weekly Report: what happened at TOVX last week (1026-1030)?
Weekly Report · 11/02 09:47
Weekly Report: what happened at TOVX last week (1019-1023)?
Weekly Report · 10/26 09:47
Weekly Report: what happened at TOVX last week (1012-1016)?
Weekly Report · 10/19 09:47
Weekly Report: what happened at TOVX last week (1005-1009)?
Weekly Report · 10/12 09:50
Weekly Report: what happened at TOVX last week (0928-1002)?
Weekly Report · 10/05 09:50
Theriva Biologics announces results from VIRAGE Phase 2b trial of VCN-01
TipRanks · 09/30 12:21
More
Webull provides a variety of real-time TOVX stock news. You can receive the latest news about THERIVA BIOLOGICS INC through multiple platforms. This information may help you make smarter investment decisions.
About TOVX
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous. Its lead product candidate is VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. VCN-01 has completed a successful Phase IIb clinical trial in first-line metastatic pancreatic cancer patients treated with gemcitabine-nab-paclitaxel standard-of-care chemotherapy.